Durable disease control with cabozantinib in metastatic chromophobe renal cell carcinoma: A rare case with promising outcomes

Chromophobe renal cell carcinoma (chRCC) is a rare RCC subtype with limited treatment data. Cabozantinib, a multikinase inhibitor, is effective in clear cell RCC but lacks robust evidence in chRCC. A 26-year-old male with metastatic chRCC achieved prolonged disease control on cabozantinib despite treatment interruptions. After first-line pazopanib failure, cabozantinib was initiated in January 2023, maintaining stable disease for over two years with only grade I toxicities. Cabozantinib appears effective in metastatic chRCC, offering prolonged stability with manageable toxicity. Further research is needed to establish its role in this rare RCC subtype.